

**Table 2.** Papers that evaluated the interrelationship among HCV infection, MC, TD and AITD

<b>Field of interest</b>	<b>Author</b>	<b>Main findings</b>
Association between HCV infection and development of TD and AITD	Giordano et al <sup>5</sup>	Thyroiditis risk is significantly increased in male HCV+ in comparison with uninfected patients
	Antonelli et al <sup>15</sup>	Higher prevalence of TSH, AbTg and AbTPO levels, and hypothyroidism in HCV+ patients ( $p < 0.001$ for all)
Association between MC+HCV and development of TD and AITD	Codes et al <sup>6</sup>	HCV+ patients, genotype 3, develop TD with a prevalence rate of 23.3% ( $p = 0.05$ ) and MC in 38% of cases ( $p = 0.02$ )
	Zarebska-Michaluk et al <sup>7</sup>	HCV+ patients develop AITD with a prevalence rate of 16.2%, and MC in 37.1%
	Castellano et al <sup>9</sup>	Case report of hypothyroidism, hemolytic anemia and cryoglobulinemia in a patient with HCV infection
	Antonelli et al <sup>10</sup>	Higher prevalence of AITD in patients with MC+HCV, not only with respect to controls (AbTPO 28% vs 9%, $p = 0.001$ ; AbTPO and/or AbTg 31% vs 12%, $p = 0.004$ ; thyroid autoimmunity 35% vs 16%, $p = 0.006$ ; subclinical hypothyroidism 11% vs 2%, $p = 0.038$ ), but also with respect to HCV+ patients without cryoglobulinemia (AbTPO 28% vs 14%, $p = 0.035$ )

AbTg: anti-thyroglobulin antibody, AbTPO: anti-thyropoxidase antibody, AITD: autoimmune thyroid disorders, HCV: hepatitis C virus, HCV+: HCV positive patients, MC: mixed cryoglobulinemia, MC+HCV: HCV-related MC, TD: thyroid dysfunctions, TSH: thyroid-stimulating hormone.